Acadian Asset Management’s Relay Therapeutics RLAY Stock Holding History

Acadian Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.89M	Sell	290,352 -166,296	-36%	-$1.49M	﹤0.01%	846
2025 Q4	$3.86M	Sell	456,648 -44,590	-9%	-$318K	0.01%	723
2025 Q3	$2.61M	Sell	501,238 -293,381	-37%	-$1.12M	﹤0.01%	827
2025 Q2	$2.75M	Buy	794,619 +112,591	+17%	+$335K	0.01%	749
2025 Q1	$1.78M	Buy	682,028 +653,081	+2,256%	+$2.56M	0.01%	788
2024 Q4	$118K	Buy	+28,947	New	+$158K	﹤0.01%	1336
2024 Q1	–	Sell	-3,875	Closed	-$42K	–	1747
2023 Q4	$42K	Buy	+3,875	New	+$32.7K	﹤0.01%	1479
2022 Q4	–	Sell	-1,744	Closed	-$38K	–	1894
2022 Q3	$38K	Buy	+1,744	New	+$38.3K	﹤0.01%	1529

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Acadian Asset Management's RLAY Position: Q1 2026 in Review

Acadian Asset Management reduced its Relay Therapeutics (RLAY) stake by 36% in Q1 2026, selling an estimated $1.49M and leaving 290,352 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Acadian Asset Management first reported a position in RLAY in Q3 2022 and has held it in 8 quarters since. The position peaked at $3.86M in Q4 2025. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

Acadian Asset Management held 290,352 shares of Relay Therapeutics worth $2.89M as of Q1 2026.
Acadian Asset Management sold 166,296 Relay Therapeutics shares in Q1 2026, an estimated $1.49M.
Relay Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #846 holding.
Acadian Asset Management first reported a position in Relay Therapeutics in Q3 2022 and has held it in 8 quarters since.
Acadian Asset Management's Relay Therapeutics position peaked at $3.86M in Q4 2025.
242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.